• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    topical suspension formulation, method for treating a skin infection or inflammation, method for treating an ophthalmic condition or disease, topical suspension composition, and topical minocycline suspension formulation to treat an individual afflicted with acne vulgaris. the invention relates to a topical suspension formulation that includes a tetracycline, a liquid medium and a polymeric gelatinizing agent. tetracycline can be in the form of its pharmaceutically acceptable salts, hydrates, or polymorphs and is in suspended form within the formulation. the liquid medium is selected so that it does not dissolve or substantially minimally dissolves tetracycline. the gelatinization agent is a polymeric hydrocarbon gelatinization agent. preferably, the tetracycline has a particle size less than or equal to about 20 microns.
    公开号:BR112015012162B1
    申请号:R112015012162-4
    申请日:2013-11-08
    公开日:2021-02-23
    发明作者:Mohammad Salman；Arturo Angel；Vijaya Swaminathan
    申请人:Hovione Scientia Limited；
    IPC主号:
    专利说明:

    Technical field
    [0001] This invention generally relates to a pharmaceutical composition and a method for preparing it, and its use in the treatment of various diseases. More particularly, the invention relates to a stable formulation of a tetracycline class of compounds, in particular minocycline, and the administration of the formulation for topical use in the treatment of infection or inflammation, and for the treatment of dermatological, ophthalmic or neurological diseases. . Background of the invention
    [0002] Acne is one of the most common conditions seen in clinical dermatological practice. And it affects all teenagers and young adults in the near future. As suggested by Anthony Mancini, the effects of acne are not limited to the skin - acne lesions among teenagers and young adults often occur during periods of high emotional sensitivity and can contribute to significant psychological distress, depression, and even an increased risk of suicide. (Anthony Mancini; “Incidence, prevalence, and pathophysiology of acne”, Johns Hopkins Adv. Stud. Med., Volume 8 (4), 100105 (2004)).
    [0003] For approximately the past thirty years, minocycline has been one of the most widely prescribed oral antibiotics in the treatment of acne. It was first introduced to the United States more than thirty years ago and has been available in different dosage forms, such as capsule, tablet, lyophilized powder for injection, and suspension (now discontinued). Minocycline was also formulated as a prolonged release powder (PLGA microspheres), for the treatment of periodontal diseases. In England, minocycline hydrochloride is also available as a gel formulation (dentomycin gel) for use in periodontal disease.
    [0004] Minocycline has a unique biological activity profile: it has both antibacterial and anti-inflammatory properties. It was first initiated as a broad-spectrum antibiotic for a variety of infectious diseases. In addition to antibacterial activity, minocycline has also been investigated for new indications, such as its use in neurological diseases as a potential neuroprotective agent and in ophthalmic diseases. However, minocycline has also been associated with certain side effects, especially in prolonged use and in high doses. Two recent review articles provide a comprehensive summary of minocycline's effectiveness and side effects in clinical use.
    [0005] Leon Kircik (“J. of Drugs in Dermatolgoy”, Nov. 2010) reviewed and compared the efficacy and safety of minocycline and doxycycline in patients with moderate to severe inflammatory acne.
    [0006] Falk Ochsendorf ("Minocycline in Acne Vulgaris - Benefits and Risks, Falk Ochsendorf, American J. Clinical Dermatology", 2010) notes that compared to the first general tetracyclines, minocycline has a better pharmacokinetic profile in men (with almost 100% of oral bioavailability), and compared with doxycycline, it was not phototoxic. However, the author suggests that compared to other tetracyclines, minocycline has an increased risk of several side effects: for example, it can induce hypersensitivity reactions affecting the liver, lung, kidneys, or multiple organs (“Drug Reaction with Eosinophilia and Systemic Symptoms [DRESS] syndrome) in the first weeks of treatment and, with long-term treatment, can cause autoimmune reactions (systemic lupus erythematosus, autoimmune hepatitis). In addition, CNS symptoms, such as dizziness, are reported more frequently with minocycline when compared to other tetracyclines. Long-term treatment with minocycline can also induce hyperpigmentation of the skin or other organs. The resistance of P. acnes to minocycline also occurs, depending on the behavior of the prescription. The author concludes that, considering the efficacy of minocycline (through oral administration), its side effect profile (from systemic exposure), resistance, price, and alternatives, is not greater considering the first antibacterial line in the treatment of acne.
    [0007] It has been suggested that minocycline, during repeated oral administration, accumulates in the skin structure and thus, transmits its antibacterial and anti-inflammatory activity. During treatment and dose they are limited by the potential side effects, as described above. These side effects are, of course, directly attributed to their systemic exposure. Systemic exposure is the dose and duration limiting factor in the treatment of acne.
    [0008] For the treatment of acne, it was appreciated that it would be desirable to have a topical minocycline formulation for the following reasons: first, it would provide the target release of minocycline at the disease site where it is required and, second, and most importantly, a Topical administration would significantly reduce (or potentially eliminate) systemic minocycline exposure. It would be reasonable to expect that systemic exposure less than minocycline would result in minimizing its side effects, enabling the potential for long-term therapy (periods longer than 12 weeks that is currently prescribed with oral treatments), and reducing some of the contraindications currently associated with serum formulations.
    [0009] There is currently no commercially available topical formulation with minocycline for acne treatment reported today. A major challenge in the development of the topical formulation of minocycline was its chemical nature: it is unstable in the form of a solution and it is also sensitive to humidity, temperature, and light. The most commonly reported impurity is formed by the epimerization of minocycline in C-4 resulting in the formation of stereoisomers of minocycline 4-epi-minocycline - a substance related to minocycline listed in the North American and European pharmacopoeias with defined limits. The 4-epiminocycline and minocycline structures are provided below:

    Consequently, it was not possible to formulate a topical formulation containing minocycline in a stable solubilized form. Periodontal topical minocycline gel (dentomycin gel; 1% minocycline gel, in clinical use in England) should be stored at refrigerator temperature, presumably due to the question of stability. Next, a brief description of the prior art is given.
    [0011] U.S. patent application No. US 2008/0188446 A1 (and references here) briefly describe the state of the art and conclude that no attempt in the past has been adequately directed to tetracycline stability and has provided a stable topical formulation for this class of compounds. US publication 2008/0188446 A1 describes a formulation for minocycline and doxycycline incorporating cyclomethicone, ST-Elastomer 10 and isopropyl myristate. Although this formulation may provide some stability for API, it contains isopropyl myristate, a known comedogenic substance, thus limiting its usefulness in the treatment of acne.
    [0012] International publication WO 2011/039637 A2 and US patent application US 2010/0310476 A1 describes an elaborate and complex constituent method for formulating tetracycline foam. A foam formulation, as claimed in the above applications, while having some stability may not release a consistent amount of the active substance to the application site for the duration of the treatment. It also requires an extra layer of complexity to release the drug formulation using a foam pump. Similarly, publication US 2011/0281827 A1 and US 2012/0087872 A1 requires the use of a pump to release a foam formulation.
    [0013] North American publication US 2012/0093876 A1 describes suspension formulations of minocycline hydrochloride in oil and petroleum for ophthalmic use. It was concluded that the minocycline hydrochloride in an oil suspension is unstable after two months with a change in color. However, an oil-based ointment suspension was found to be stable enough for further investigation by these researchers. We found that, surprisingly, minocycline can indeed be stabilized, for example, an oily suspension gel formulation (details of which are described, more completely below) is quite stable at room temperatures for one year, the stability test was conducted.
    [0014] It has been appreciated that there remains a medical need for a stable, practical, commercially viable and easy to manufacture and easy to use topical formulation for the tetracycline class of compounds, especially, but not exclusively comprising minocycline and doxycycline, and particularly comprising minocycline , whose formulation can be administered to a patient needing to treat infections or inflammation and to treat dermatological, ophthalmic or neurological diseases. Summary of the invention
    [0015] In a general aspect, the invention relates to a topical suspension formulation comprising a tetracycline, a liquid medium and a polymeric gelatinizing agent. Tetracycline can be in the form of a pharmaceutically acceptable salt, hydrate, or polymorph of the same and is in a suspended form within the formulation. The liquid medium is selected so that it does not dissolve or minimally or substantially dissolves tetracycline. The gelatinizing agent is preferably a polymeric hydrocarbon gelatinizing agent. Tetracycline preferably has a particle size (D90) less than or equal to about 20 microns.
    [0016] A liquid medium that does not dissolve or substantially and minimally dissolves tetracycline is suitably one that results in less than 5% of the active ingredient of tetracycline being dissolved in the medium at room temperature after 2 hours, as measured by HPLC.
    [0017] According to one aspect, the present invention provides a topical suspension formulation comprising: a tetracycline, or a pharmaceutically acceptable salt, hydrate, or polymorph of the same in a suspended form within the formulation; a liquid medium that does not dissolve or substantially and minimally dissolves tetracycline; and a polymeric hydrocarbon gelatinizing agent.
    [0018] Preferably, the particle size of the tetracycline is less than or equal to 20 microns.
    [0019] In another aspect, the invention provides a topical minocycline suspension formulation for the treatment of an individual afflicted with acne vulgaris, the composition consisting essentially of a pharmaceutically effective amount of minocycline, a hydrophobic liquid medium that does not dissolve or dissolve minimally tetracycline, and a polymeric hydrocarbon gelatinizing agent to thicken the composition, where: the hydrophobic liquid medium is characterized as (a) resulting in less than 5% of the tetracycline active ingredient being dissolved in the medium at room temperature after 2 hours as determined by HPLC, and / or (b) results in less than 4% 4-epinocycline (when minocycline is used as the active ingredient) when stored for 1 month at room temperature, as determined by HPLC.
    [0020] In a further aspect, the invention provides a topical suspension formulation comprising: a tetracycline, or its pharmaceutically acceptable salts, hydrates, or morphs in a suspended form within the formulation; a non-comedogenic, hydrophobic liquid medium that does not dissolve or substantially and minimally dissolves tetracycline; and a polymeric hydrocarbon gelatinizing agent to thicken the suspension.
    [0021] In another aspect, the invention provides a method for treating an infection or inflammation of the skin, the method comprising topical administration to an individual in need of said treatment with a suspension formulation according to the invention.
    [0022] The invention also provides a method for treating an infection or inflammation of the skin, the disease being characterized as acne, particularly acne vulgaris, or rosacea.
    [0023] The invention also provides a method for treating an ophthalmic disease or condition, the method comprising topical administration to a surface of the eye of an individual in need of said treatment with a suspension formulation according to the invention.
    [0024] In the topical suspension formulation of the invention, tetracycline is preferably minocycline, especially crystalline free base minocycline.
    [0025] An advantage of the present formulation is its stability compared to state-of-the-art formulations, particularly with respect to discoloration as a function of time and the amount of impurities, including the breakdown of products of the active material, such as 4-epi-minocycline . The formulations of the invention are stable for at least 1 year (with respect to the above characteristics) at room temperature (25 °).
    [0026] The topical suspension formulation that includes minocycline preferably has a concentration of 4-epi- minocycline that is not more than 4% after storage for 6 months in real time (25 ° C / 60% relative humidity (RH) and under conditions of accelerated stability (40 ° C / 75% RH), as determined by HPLC analysis, or the topical suspension formulation that includes minocycline has a concentration of 4-epinocycline in the minocycline suspension formulation stored at 40 ° C / 75% RH for a month which results in less than 3% 4-epi-minocycline, as determined by HPLC Preferably, the topical suspension formulation that includes minocycline has a concentration of 4-epi minocycline in the minocycline suspension formulation when stored at 40 ° C / 75% RH for three months results in less than 4% of 4-epi-minocycline, as determined by HPLC analysis. minocycline can have a concentration not greater than 4 % of 4- epi minocycline after storage for 12 months in real time (25 ° C / 60% RH) under stable conditions, as determined by HPLC analysis. The percentages expressed above are by weight of minocycline.
    [0027] In the topical suspension formulation, the liquid medium can be a non-comedogenic liquid medium. The non-comedogenic liquid medium can be one or more of a mineral oil, a light mineral oil, a minimally comedogenic oil and an additional non-comedogenic oil. The non-comedogenic liquid medium can, for example, be mineral oil.
    [0028] The non-comedogenic liquid medium can be characterized as (a) resulting in less than 5% of the active ingredient of tetracycline being dissolved in the medium at room temperature after 2 hours, as measured by HPLC, and / or (b) resulting in less than 4% 4-epi-minocycline, if minocycline is used as the active ingredient, when stored for 1 month at room temperature, as measured by HPLC. Preferably, the mineral oil can constitute about 70% to about 90% of the suspension formulation. Or mineral oil can make up at least 90% of the suspension formulation. Or mineral oil can make up at least 70% of the suspension formulation.
    The polymeric hydrocarbon gelatinizing agent can be any appropriate gelatinizing agent, and is preferably VERSAGEL®M (200, 500, 750 or 1600) which are commercially available, or a gel comprising an oil and one or more gelatinization polymers.
    [0030] The topical suspension formulation can be free of a skin penetration enhancing agent or an excipient that works primarily or only as a skin penetration enhancer. In a preferred aspect, the formulation of the invention is free of isopropyl myristate.
    [0031] The formulation is also preferably free of a compound that results in the dissolution of the tetracycline active ingredient. The compound that results in the dissolution of the tetracycline active ingredient can include one or more of water, hydrophilic solvents and emollient esters.
    [0032] The liquid medium or the vehicle may be a combination of a non-comedogenic medium or vehicle and a comedogenic medium or vehicle with the non-comedogenic medium or vehicle being present in an amount greater than the comedogenic medium the vehicle.
    [0033] The topical suspension formulation is preferably not a foam, and is also preferably non-foamable. It is preferably free of a foam adjuvant. The formulation of the invention is preferably free of propellant.
    [0034] The topical suspension composition may additionally include one or more of a sunscreen agent, a fragrance and a dye or dye.
    [0035] In a preferred aspect of the invention, the formulation is free of silicone thickening agents, in particular free of hydrophobic, non-hygroscopic silicone thickening agents.
    [0036] The topical suspension formulation can be used in a method of treating an infection or inflammation of the skin, the method can include topical administration to an individual in need of said treatment with a suspension formulation described here. The disease can be characterized as being acne or rosacea.
    [0037] The topical suspension formulation can be used in a method for treating an ophthalmic disease or condition, the method comprising administering topically, on a surface of the eye of an individual in need of said treatment, a suspension formulation described herein.
    [0038] In another embodiment, the topical suspension formulation may consist essentially of a pharmaceutically effective amount of minocycline or a pharmaceutically acceptable salt, hydrate, or polymorph thereof, a non-comedogenic liquid medium that does not dissolve or minimally dissolve tetracycline , and a gelatinizing agent to thicken the composition and, optionally, one or more of 4-epi monocycline, colorants, dyes, fragrances and a sunscreen material. The formulation can include one or more of the characteristics described above or here.
    The topical suspension formulation may consist of a pharmaceutically effective amount of minocycline or a pharmaceutically acceptable salt, hydrate, or polymorph thereof, a non-comedogenic liquid medium that does not dissolve or minimally dissolve minocycline, and a gelatinization agent for thicken / thicken the composition. The formulation can include one or more of the characteristics described above or described here.
    The topical suspension formulation can consist of a pharmaceutically effective amount of minocycline or a pharmaceutically acceptable salt of it, hydrate, or polymorph of it, a non-comedogenic liquid medium that does not dissolve or minimally dissolve minocycline, and a people of gelatinization to thicken the composition and 4-epi minocycline and, optionally, one or more of a liquid comedogenic medium present in a smaller amount than that of the non-comedogenic liquid medium, colorants, tinctures, fragrances and sunscreen material. The formulation can include one or more of the characteristics described above or described here.
    [0041] In another general aspect, a topical minocycline suspension composition is provided for the treatment of an individual afflicted with acne vulgaris. The composition consists essentially of a pharmaceutically effective amount of minocycline or a pharmaceutically acceptable salt, hydrate, or polymorph thereof, a liquid medium that does not dissolve or minimally dissolve tetracycline, and a gelatinizing agent to thicken the composition. The liquid medium is characterized as (a) resulting in less than 5% of the active ingredient tetracycline being dissolved in the medium at room temperature after 2 hours, and / or (b) resulting in less than 4% of 4-epi minocycline (when minocycline is used as the active ingredient) when stored for 1 month at room temperature. The formulation can include one or more of the characteristics described above or described here.
    [0042] In another general aspect, a topical minocycline composition is provided for treating acne vulgaris. The composition consists essentially of a pharmaceutically effective amount of minocycline or a pharmaceutically acceptable salt, hydrate, or polymorph of it, a hydrophobic liquid medium that does not dissolve or minimally dissolve minocycline, and a polymeric hydrocarbon gelatinizing agent to thicken / thicken the composition . Preferably, the composition contains less than 4% 4-epi minocycline after storage for 6 months in real time (25 ° C / 60% RH) and under conditions of accelerated stability (40 ° C / 75% RH), as determined through HPLC analysis. The carrier agent can include a hydrophobic solvent that can maintain minocycline in the suspended form so that the solubility of minocycline in the suspended form is not greater than 5%. The hydrophobic liquid medium can be characterized as (a) resulting in less than 5% of the active ingredient tetracycline being dissolved at room temperature after 2 hours as determined by HPLC, and / or (b) resulting in less than 4% of 4 -epi-minocycline (when minocycline is used as the active ingredient) when stored for 1 month at room temperature as determined by HPLC.
    [0043] In another general aspect, the invention relates to the topical suspension formulation that includes a tetracycline or a pharmaceutically acceptable salt, hydrate, or polymorph of the same, a non-comedogenic hydrophobic liquid medium, and a gelatinizing agent of polymeric hydrocarbon. Tetracycline, or its pharmaceutically acceptable salts, hydrates, or morphs is in a suspended form within the formulation. The non-comedogenic hydrophobic liquid medium does not dissolve or substantially and minimally dissolves tetracycline. The polymeric hydrocarbon gelatinizing agent thickens the suspension.
    [0044] The topical suspension formulation may include one or more of the characteristics described here.
    [0045] The preferred aspects of the invention are represented in the description below, it should be understood that these are given as an illustration of the invention and not as limiting them. Other features and advantages of the invention will be apparent from the description and claims. Detailed description of the invention
    The present invention relates to a tetracycline suspension formulation for tropic administration comprising an active compound belonging to the tetracycline class of the compounds, or a pharmaceutically acceptable salt or hydrate or polymorph thereof, substantially stabilized as a suspension in a medium appropriate liquid in which tetracycline was not or was substantially and minimally soluble in, and which is suitable for topical application in humans requiring treatment for inflammatory or dermatological or ophthalmic infection or disease. The suspension medium is preferably comprised of a non-comedogenic liquid, suitable for topical application and, for example, selected from the list in the US FDA Guide to Inactive Ingredients. In a particularly preferred embodiment, the suspension medium is mixed with a gelatinizing agent comprising a mineral gelatinization oil, such as commercially available, VERSAGEL®M (Versagel®M750, for example, contains a mixture of white mineral oil (90- 100%) + ethylene / propylene / styrene copolymer (2.5 - 10%) + butylene / ethylene / styrene copolymer (1 - 2.5%), and butylated hydroxyl-toluene (<0.1%).
    [0047] A comedogenic ingredient is variably defined as an ingredient that (a) tends to clog pores, especially due to the shape of blackheads, and (b) tend to produce or aggravate acne. It is reported in the literature that comedogenic excipients can vary in their comedogenicity with some excipients being highly comedogenic, some being moderately comedogenic and others being moderately comedogenic. As used here, a non-comedogenic ingredient is one that does not tend to clog pores and / or produce or aggravate acne.
    [0048] In one aspect, the present invention relates to a topical formulation of a tetracycline class of compounds comprising at least one tetracycline or a pharmaceutically acceptable salt or hydrate or polymorph thereof, stabilized as a suspension in an appropriate medium in which tetracycline is either substantially and minimally and soluble, and which is suitable for topical application in humans requiring treatment for infection or inflammation or ophthalmic disease. Preferably, the tetracycline class of compounds includes minocycline and doxycycline. More preferably, tetracycline is specifically minocycline or a pharmaceutically acceptable salt, hydrate, or polymorph of the same. In a preferred aspect, the suspended medium is compressed from a non-comedogenic liquid medium, suitable for topical application and preferably selected from the US FDA guide list of inactive ingredients. Particularly and preferably, the suspension medium is selected from mineral oils or similar oils. The suspension medium can be mixed with a gelatinizing agent comprising gelatinized mineral oils, such as commercially available in Versagel®M (a mixture of white mineral oil + ethylene / propylene / styrene copolymer + butylene / ethylene / styrene + toluene copolymer) butylated hydroxy as an optional antioxidant).
    [0049] The present invention is also related to a method for treating dermatological or ophthalmic diseases by administering the tetracycline suspension formulation to humans or animals requiring such treatments. In one aspect, the tetracycline suspension formulation is administered twice daily to the individual in need of said treatment. In another aspect, the suspension formulation is administered once a day at night before bed for patients in need of such treatment. Alternatively, the suspension formulation is administered the night before bed followed by topical administration of benzoyl peroxide in the morning to a patient in need of such treatment. Or the tetracycline class of the compounds is combined with the additional anti-acne active agents, so that the retinoid class of compounds, in a suspension formulation. In yet another aspect, the tetracycline class of the compounds is combined with a sunscreen in a suspension formulation.
    [0050] The tetracycline suspension formulation can consist of the tetracycline active ingredient, the non-comedogenic liquid medium and the gelatinizing agent. The tetracycline active ingredient can be, for example, minocycline or doxycycline or a pharmaceutically acceptable salt, hydrate, or polymorph of the same. The non-comedogenic liquid medium can be a mineral oil. The gelatinizing agent can be a gelatinized mineral oil or one or more gelatinization polymers. It should be understood that a composition consisting of the active ingredient of tetracycline, the non-comedogenic liquid medium and the gelatinizing agent may, over time, include some degradation of the product of the active ingredient of tetracycline. Thus, in another aspect, the composition may consist of the active ingredient of tetracycline, the non-comedogenic liquid medium, the gelatinizing agent and some degradation product of the active ingredient of tetracycline. Furthermore, it is understood that a composition consisting of the active ingredient of tetracycline, the non-comedogenic liquid medium and the gelatinizing agent also includes a comedogenic liquid medium present in an amount that does not result in measurable or perceptible comedogenic effects for individuals using the formulation with the comedogenic agent present. As explained above, over a period of time, the formulation may include some degradation product of the active ingredient tetracycline. Thus, the composition can consist of the active ingredient tetracycline, the non-comedogenic liquid medium, the gelatinizing agent, an amount of a comedogenic liquid medium and some degradation product of the tetracycline active ingredient.
    [0051] The tetracycline suspension formulation can consist essentially of the tetracycline active ingredient, the non-comedogenic liquid medium to act as a vehicle for the tetracycline active ingredient in the form of a suspension, and the gelatinizing agent to thicken the composition. The active ingredient of tetracycline can be, for example, minocycline or doxycycline or a pharmaceutically acceptable salt, hydrate, or polymorph of the same. The non-comedogenic liquid medium can be a mineral oil. The gelatinization agent can be a gelatinized mineral oil or one or more gelatinization polymer. It is to be understood that the tetracycline suspension formulation consisting essentially of the active ingredient of tetracycline, the non-comedogenic liquid medium to act as a vehicle of the active ingredient of tetracycline in the form of a suspension, and the gelatinizing agent to thicken / thicken the composition may further include additional ingredients that are not intended to function as a vehicle or thickening agent. For example, the composition may also include dyes, dyes, fragrances and sunscreen materials. Examples of sunscreen agents that can be used include zinc oxide, titanium dioxide, benzophenones such as avobenzone, oxybenzone and dioxibenzone, octyl-salicylate-octocrilaene, and aminobenzoic acid.
    [0052] The tetracycline suspension formulation can consist essentially of the tetracycline active ingredient, the non-comedogenic liquid medium to act as a vehicle of the tetracycline active ingredient in the form of a suspension, a small amount of a comedogenic liquid medium to act as a vehicle of the tetracycline active ingredient, and the gelatinizing agent to thicken the composition. The active ingredient of tetracycline can be, for example, minocycline or doxycycline or a pharmaceutically acceptable salt, hydrate, or polymorph of the same. The non-comedogenic liquid medium can be a mineral oil. The gelatinization agent can be a gelatinized mineral oil or one or more gelatinization polymer. It is to be understood that the tetracycline suspension formulation consisting essentially of the active ingredient of tetracycline in the form of a suspension, the liquid comedogenic medium to act as a vehicle of the active ingredient tetracycline in the form of a suspension, and the gelatinizing agent to thicken the composition may further include additional ingredients that are not intended to function as a vehicle or thickening agent. For example, the composition may also include dyes, dyes, fragrances and sunscreen materials. Examples of sunscreen agents that can be used include zinc oxide; benzophenone titanium dioxide such as avobenzone, oxybenzone and dioxibenzone; octyl octylene sailicylate; and aminobenzoic acid. The composition consisting essentially of the tetracycline active ingredient, the non-comedogenic liquid medium to act as a vehicle of the tetracycline active ingredient in the form of a suspension, the comedogenic liquid medium to act as a vehicle of the tetracycline active ingredient in the form of a suspension. a suspension, and the gelatinizing agent to thicken the composition, may further include degradation of the 4-epinocycline product.
    [0053] The tetracycline suspension formulation of the invention contains at least one tetracycline or a pharmaceutically acceptable salt or hydrate or polymorph thereof, substantially stabilized as a suspension, as determined by the HPLC analysis of the samples stored in real time (25 ° C / 60% RH) and under conditions of accelerated stability (40 ° C / 75% RH). Preferably, at least 90% of the active tetracycline compound is retained after 6 months of real-time storage and accelerated stability conditions, as described above. More preferably, at least 90% of the active tetracycline compound is retained after 12 months of real-time storage under stability conditions, as described above. Preferably, when the tetracycline suspension contains minocycline as an active tetracycline, stabilization is also determined by the levels of 4-epi-minocycline, as determined by HPLC analysis. Preferably, the minocycline suspension formulation contains no more than 6% 4-epi-minocycline after storage for 6 months in real time and accelerated stability conditions, as described above. Preferably, the minocycline suspension formulation contains no more than 5% 4-epi-minocycline after storage for 6 months in real time and accelerated stability conditions, as described above. Preferably, the minocycline suspension formulation contains no more than 4% 4-epi-minocycline after storage for 6 months in real time and under tight stability conditions, as described above. More preferably, the minocycline suspension formulation contains no more than 3% 4-epi-minocycline after storage for 6 months in real time and under accelerated stability conditions, as described above. Even more preferably, the minocycline suspension formulation contains no more than 4% 4-epi minocycline after storage for 12 months in real time under conditions of stability, as described above.
    The suspension formulation of the invention can contain 0.01% to 20% (weight by weight) of the active tetracycline compound. Preferably, the suspension formulation contains 0.05% to 10% (weight by weight) of the active tetracycline compound.
    [0055] The tetracycline suspension formulation refers to a formulation that adequately contains less than 5% (weight by weight) of the active dissolved tetracycline. Preferably, the tetracycline suspension formulation contains less than 1% (weight by weight) of the dissolved active tetracycline. More preferably, the tetracycline suspension formulation contains less than 0.5% (weight by weight) of the dissolved active tetracycline. The amount of active ingredient dissolved is determined by HPLC analysis.
    The suspension formulation of the invention preferably comprises a specific particle size of the active tetracycline. Preferably, the active suspended tetracycline particle size is less than or equal to 20 microns. In a preferred aspect, 90% of the suspended tetracycline particles are less than 10 microns in size. Preferably, the particle size ranges from about 2 microns to about 10 microns, more preferably from about 3 microns to about 8 microns, as a range for optimal penetration of the active ingredient tetracycline into the skin. For a particle size above about 8 to 10 microns, it is believed to be little if any penetration into the skin and for a particle size below about 2 to 3 microns can have a lot of penetration into the skin, such as that level in minocycline blood are greater than desired. In addition, if the particle size is also smaller, there is an increased probability that some of the active ingredients of tetracycline can dissolve and be subjected to degradation. Thus, preferably, the D90 value can be a value that is from about 2 microns to about 10 microns. Therefore, the D90 can be 2 microns, 3 microns, 4 microns, 5 microns, 6 microns, 7 microns, 8 microns, 9 microns or 10 microns. An important factor in the selection of the particle size is that a sufficient amount of the particles is about 2 to about 8 microns to penetrate sufficiently into the skin.
    [0057] The formulations were prepared using two batches of minocycline active ingredient of different particle size distribution. Both batches are believed to be suitable for use as an active ingredient of minocycline in a typical suspension formulation according to the invention. The particle size distribution was as follows:

    [0058] The inventors made formulations according to Example 1 using the two batches of minocycline ingredient described above. The particle size parameters measured using a Malvern 2000 Master Dimensioner after storage for the indicated time are provided below:

    [0059] The above data indicates that the minocycline particle sizes remain substantially the same during formulation and after storage.
    [0060] Therefore, in one aspect of the invention, the tetracycline active ingredient has a D90 value which is a unique value from about 4 to about 10 microns. For example, the D90 can be 4 microns, 5 microns, 6 microns, 7 microns, 8 microns, 9 microns, or 10 microns, or fractional values between them, as will be understood by those skilled in the art. In another aspect of the invention, the tetracycline active ingredient has a D90 value that is a unique value from about 4 to about 10 microns and a D50 value that is a unique value from about 1 to about 5. In another aspect of the invention, the tetracycline active ingredient has a D90 value that is a unique value from about 4 to about 10, a D50 value that is a unique value from about 1 to about of 5, and a D10 value that is a single value from about 0.5 to about 1.5.
    [0061] The particle size distribution described above should be understood by referring to both the particle size of the active ingredient used in the formulation, as well as the particle size of the active ingredient present in the suspension formulation. Therefore, a lost particle agglomeration with a D90, D50, D10 or general particle size that breaks within the particles when agitated or formulated is intended should be included in the invention because the particles in the suspension are within the particle size described here and are expected to provide the desired therapeutic effect. The particles to be used in the formulation can be gently agitated to reduce any agglomerations formed intentionally or unintentionally. The particle size and particle size distribution of the tetracycline particles can be measured using a Malvern master size. This measurement can be made of the active ingredient before the formulation and the suspension formulation itself.
    [0062] Tetracyclines include all compounds reported from this generic class of compounds, would be known to a person skilled in the art. Preferably, the tetracycline is doxycycline or minocycline, or its pharmaceutically acceptable salts, hydrates, or polymorphs. More preferably, the active tetracycline refers to minocycline or its pharmaceutically acceptable salts, hydrates, or polymorphs. The suspension formulation preferably contains 0.01% to 20% (weight by weight) of the active tetracycline compound. More preferably, the suspension formulation contains 0.05% to 10% (weight by weight) of the active tetracycline compound. Even more preferably, the suspension formulation contains 0.1% to 10% (weight by weight) of minocycline or its pharmaceutically acceptable salts, hydrates, or polymorphs.
    [0063] Minocycline is sparingly soluble in water, slightly soluble in alcohol, practically insoluble in chloroform and in ether, and soluble in solutions of alkali hydroxides and carbonates. Minocycline is highly sensitive and should be stored in airtight containers and protected from light to prevent degradation. Minocycline instability has been described in North American publication No. US 2013 0064777, the reference of which can be made for further details, and the contents of which are incorporated herein by reference in their entirety, for the selection of excipients for use with tetracyclines, where a compatibility study reported that the difference shown in hydrophilic solvents was incompatible with minocycline while hydrophobic emollients and waxes were compatible with minocycline, except for pomegranate seed oil. Publication No. US 20130064777 also refers that all fatty alcohols, as well as some fatty acids (such as stearic acid, oleic acid, palmitic acid) surfactants (sucrose fatty esters, however, not all of them dissolved in oil) and some additive (Aerosil and menthol) were compatible with minocycline. Isostearic acid, EthocelTM and titanium dioxide polysorbates, sorbitan esters (Span®), alkyl polyoxyethylene ethers (BrijTM), PEG stearates (MyrjTM) have been reported as not being compatible with minocycline. The publication also reports that the addition of water caused rapid degradation of minocycline with the addition of antioxidants (alpha-tocopherol, BHA / BHT and propyl gallate) do not prevent such degradation. The publication concludes that compatible excipients become incompatible in the presence of water and the addition of antioxidant does not remedy this result.
    [0064] This invention also relates to the use of a non-comedogenic liquid medium that does not solubilize the tetracycline class of the compounds, for the preparation of a suspension formulation. Preferably, the non-comedogenic liquid medium for the suspension formulation refers to the mineral, light mineral, other non-comedogenic oils and minimally comedogenic oils. In a preferred aspect, the non-comedogenic liquid medium for formulating the suspension refers to mineral oil. In a preferred aspect, the tetracycline suspension formulation contains 70% to 90% mineral oil. In a more preferred aspect, the tetracycline suspension formulation contains approximately 90% mineral oil. Mineral oil can be made up of a combination of mineral oil itself and mineral oil which is a component of a second component, such as a gelatinizing agent in the form of a polymeric hydrocarbon gel.
    [0065] Preferably, the polymeric hydrocarbon gelatinizing agent is a mixture of a mineral oil and one or more copolymers based on one or more monomers selected from alkene monomers, particularly C1-C10, or C1 alkene monomers to C6, or C2 to C4, and phenylalkene monomers, particularly C1-C10 phenylalkene monomers, or C1 to C6, or C2 to C4, or is a gel comprising an oil and one or more gelatinization polymers.
    [0066] One or more copolymers can comprise an ethylene / propylene / styrene copolymer, and / or one or more copolymers can comprise a butylene / ethylene / styrene copolymer.
    [0067] The suspension formulation may further comprise an anti-oxidant, particularly, butylated hydroxy toluene.
    [0068] In a preferred aspect, the polymeric gelatinizing agent comprises ethylene / propylene / styrene copolymer and debutylene / ethylene / styrene copolymer and butylated toluene-hydroxy as an optional antioxidant.
    [0069] Preferably, the gelatinizing agent comprises a polymeric hydrocarbon gel such as commercially available, Versagel®M (Versagel contains a mixture of white mineral oil (90-100%) + ethylene / propylene / styrene copolymer (2.5 -10%) + butylene / ethylene / styrene copolymer (1-2.5%) or similar gelatinizing agents Surprisingly, no aggregates of the active tetracycline compound were observed over a period of approximately one year with the use of size particle size of the active tetracycline, as described above.
    [0070] Another non-comedogenic liquid medium can be chosen instead of or in addition to mineral oil. The non-comedogenic liquid medium is selected based on its ability to keep the tetracycline in suspension, that is, the non-comedogenic liquid solubilizes minimally or does not solubilize the tetracycline compound. By selecting a liquid medium that minimally solubilizes or does not solubilize the tetracycline compound, the stability of the tetracycline compound is improved. The procedure for determining whether or not a particular liquid medium minimally solubilizes or does not solubilize the tetracycline compound is well known. Specifically, an appropriate liquid medium is selected by (1) testing the solubility of the active agent tetracycline in various liquid medium solvents, (2) identifying those that do not solubilize or minimally solubilize the active agent of tetracycline followed by (3) inclusion in the composition of said liquid medium solvent which does not solubilize or minimally solubilize the active agent. Preferably, the tetracycline compound is completely insoluble or minimally solubilizes in the composition that includes the liquid medium. Examples of suitable liquid media include mineral oil, paraffin oil, fatty acids such as castor oil / peanut oil, sunflower oil, light mineral oil, squalene, squalane, triglycerides, monoesters and diesters, fractionated coconut oil and oil of silicone. It should be understood that the above test protocol for the non-comedogenic liquid medium can be applied to determine whether a minimally comedogenic liquid medium will be appropriate with respect to the extent of solubility of the tetracycline ingredient in the medium.
    [0071] In particular, the non-comedogenic liquid medium can include any liquid medium that (a) results in less than 5% of the active ingredient tetracycline being dissolved in the medium at room temperature after 2 hours, and / or (b) results in less than 4% 4-epi-minocycline (when minocycline is used as the active ingredient) when stored for 1 month at room temperature. It should be understood that the test report above for the non-comedogenic liquid medium can be applied to determine whether a minimally comedogenic liquid medium will be appropriate with respect to the extent of solubility of the tetracycline ingredient in the medium and the formation of 4-epi-minocycline.
    [0072] In addition, for inclusion of non-comedogenic liquid medium excipients, it should be understood that the formulation may also include excipient from the liquid comedogenic medium. For example, it is reported that medium-comedogenic excipients can be included in a formulation and do not create a problem when used in diluted concentrations. Said medium-comedogenic excipients include avocado oil, corn oil, D&C Red, number 4, 6, 7, or 8, glyceryl stearate, lanolin, lauryl alcohol, and safflower oil. Another liquid comedogenic medium that has a high or medium comedogenic rating can, of course, be used in the formulation in small enough amounts to not cause acne.
    [0073] An objective of the invention is to prevent significant degradation of the active ingredient of tetracycline that occurs when the compound is in solution. To avoid this category of degradation, the formulation does not typically include water, hydrophilic solvents or emollient esters. The formulations can therefore be characterized by being free of water, and / or free of a hydrophilic solvent and / or free of an emollient ester in an amount sufficient to cause solubilization of tetracycline or degradation of tetracycline.
    [0074] The formulations can also be characterized as being free of a skin penetration enhancer or an excipient that works primarily or only as a skin penetration enhancer. In particular, the formulation is free of a penetration enhancer in an amount that induces tetracycline to enter the bloodstream at an undesirable level. In other words, the formulation may include an excipient that functions, minimally, as a penetration enhancer, but is present primarily for another purpose, for example, to thicken the formulation, or as a vehicle, but the penetration enhancer may not induce tetracycline to be present in the bloodstream at an undesirable level.
    [0075] The following examples are intended as illustrative of the invention, without being limiting in any way. Example 1
    [0076] A tetracycline suspension formulation for topical administration was prepared using the ingredients as listed in Table 1 below: Table 1

    [0077] The minocycline-free base crystalline (having desired particle size distribution) was added to the mineral oil and the mixture stirred for about 30 minutes. Versagel®M-750 was then added slowly and the suspension stirred for another 30 minutes.
    [0078] The suspension formulation as described above was prepared in different climbs (1 kg and 5 kg) and with different resistance from minocycline. The homogeneity of the suspension was confirmed by HPLC analysis of multiple samples from different locations in the mixing vessel. To determine the compatibility of the packaging, the suspension formulation from Example 1 was packaged in a glass and aluminum jar and laminated tubes suitable for topical packaged formulations. The suspension formulation samples were stored during real time and accelerated stability studies according to the ICH stability storage guide. The USP HPLC method was used to determine minocycline and related substances. The particle size analysis of the suspension formulation after approximately one year at 25 ° C / 40% RH did not show agglomeration or change when compared to the particle size distribution of the starting minocycline drug substance. Example 2
    [0079] A tetracycline suspension formulation for topical administration was prepared using the ingredients as listed in Table 2 below: Table 2

    The minocycline-free base crystalline (having desired particle size distribution) was added to the capric triglycerides and the mixture stirred for about 30 minutes. Versagem®M-750 was then added slowly and the suspension was stirred for another 30 minutes. The suspension formulation samples were tested for stability at 25 and 40 degrees Celsius over a period of three months. The USP HPLC method was used to determine minocycline and related substances. Samples of the suspension formulation were first dissolved in THF before dilution for HPLC analysis.
    [0081] Specific embodiments of the invention are described below as examples. These examples are for the purpose of illustration only and should not be taken in any way as limiting the scope of protection of the present invention. Stability Study:
    The minocycline suspension formulations prepared in Examples 1 and 2 were tested for stability through determination and minocycline and 4-epi-minocycline. The samples in Examples 1 showed that minocycline remained stable for a period of six months at 40 ° C, while the samples in Example 2 showed a change in heat, indicating the formation of degradation products. In addition, the samples in Example 2 showed settlement after 3 months at 40 ° C. The extent of C-4 epimerization of minocycline is one of the keys to stability indicating impurities; The sample from Example 1 showed less than 1% 4-epi minocycline over a period of six months at 40 ° C.
    [0083] The minocycline suspension formulation of Example 1 was packaged in aluminum and laminated tubes for stability and packaging compatibility studies according to the ICH stability protocols (Table 3). The suspension formulation showed excellent stability over a period of six months in accelerated (40 ° C / 75% RH) and for a year in real time under conditions (25 ° C / 60% RH). This stability and packaging compatibility studies are continuous, based on the existing stability data, a service life of at least eight months is designed for the minocycline suspension described in Example 1. Table 3 Batch 3663-46 (1% gel minocycline) - ICH stability and compatibility study

    Therefore, in one aspect of the invention, a minocycline suspension formulation when stored at 40 ° C / 75% RH for one month results in less than 0.3% 3-epi minocycline. In another aspect of the invention, a minocycline suspension formulation when stored at 40 ° C / 75% RH for one month results in less than 0.26% 4-epi-minocycline. In another aspect of the invention, a minocycline suspension formulation when stored at 40 ° C / 75% RH for three months results in less than 0.4% 4-epi minocycline. In another aspect of the invention a suspension formulation minocycline when stored at 40 ° C / 75% RH for three months results in less than 0.34% 4-epi minocycline. In another aspect of the invention, a minocycline formulation when stored at 40 ° C / 75% Rh for six months results in less than 2% 4-epi minocycline. In another aspect of the invention, a minocycline suspension formulation when stored at 40 ° C / 74% RH for six months results in less than 1.4% 4-epi minocycline.
    [0085] It should be understood that the measurement of 4-epi-minocycline is based on the amount of minocycline initially present. Therefore, if the amount of 4-epi-minocycline is measured to be 0.5%, that value is related to the initial amount of minocycline.
    [0086] The impurity data that is reported above are based on a small batch size. In the inventors' experiment, it is expected that the level of 4-epi-minocycline will be increased in large batches. For example, the initial levels of 0.14% 4-epi-minocycline impurities listed above will also be higher in large batches, such as those on a commercial scale. Because the pharmacopoeia requirements for 4-epi-minocycline are less than 6%, the amount of 4-epi-minocycline in the formulations described here must be less than 6%.
    [0087] The data above shows that the rate of formation of 4-epi-minocycline appears to occur more rapidly initially than the last. Without wishing to be bound by any particular theory, in addition to the observations above, the inventors believe that the rate of formation of 4-epi-minocylcine occurs more rapidly initially than the latter due to the solubility of minocycline in the suspension.
    [0088] As evident from the stability data above, the topical suspension minocycline formulation has approximately 300% increase in the impurity of 4-epi- minocycline after six months to one year of storage at 25 ° C / 60% of RH and 30 ° C / 65% RH. When stored at 40 ° C / 75% RH for 1-3 months in the formulation it has an approximately 100% increase in, or double the amount of 4-epi minocycline impurities.
    [0089] The impurity data that is reported above is based on a smaller batch size. In the inventors' experiment, the level of 4-epi-minocycline is expected to be increased in larger batches. The pharmacopoeia requirements for 4-epi-minocycline are less than 6% which is believed to be an appropriate maximum value for the presence of 4-epi-minocycline in the topical suspension of minocycline, despite any value between about 3% at about 6% is an appropriate specification for the maximum level of 4-epinocycline. Permeation studies:
    The minocycline suspension formulation of example 1 above was evaluated ex vivo, for skin permeation (Franz Cel and Human Skin). The minocycline suspension formulation as described in Example 1 (20 μL, 1% of the gel in suspension) was applied to 2 cm2 of the skin surface and permeation was studied over a period of 48 hours. The results showed that there was approximately five times more minocycline present in the epidermis and dermis when compared to the recipient's chamber (approximately 530 ng in epidermis and dermis versus approximately 100 ng in the recipient's chamber) - this suggests that the minocycline formulation as described in Example 1, in topical administration, will potentially result in concentrations at low and comparatively higher (than systemic) systemic exposure in the epidermis, and in the dermis. In this ex vivo permeation study, the majority of minocycline was not absorbed and determined on the washed surface (Table 4). Table 4: Distribution through the skin donorDistribution of minocycline and appearance of 4-epi minocycline around human skin ex vivo. For 48 hours from a single application of 1% minocycline gel. Mean + SE, n = 3 donors, as the percentage of dose applied and total mass (1 g / 2-cm2)

    [0091] Although several particular forms of the invention have been illustrated and described, it will be apparent that various modifications and combinations of the invention detailed in the text can be made without departing from the scope of protection of the invention. For example, references to specific utilities are not intended to be limiting in any way and other utilities and applications could be replaced and remain within the scope of protection of the invention. Consequently, they do not intend the invention to be limited, except when through the appended claims.
    权利要求:
    Claims (32)
    [0001]
    1. Topical suspension formulation, characterized by the fact that it comprises: - a tetracycline, or a pharmaceutically acceptable salt, hydrate, or polymorph of the same in a suspended form within the formulation; - a liquid medium which does not dissolve less than 5% of the active ingredient from the tetracycline class determined by HPLC at room temperature after 2 hours and comprises mineral oil; and - a polymeric hydrocarbon gelatinizing agent, the particle size of the tetracycline having a D90 value of 4 micrometers to 10 micrometers.
    [0002]
    2. Topical suspension formulation according to claim 1, characterized by the fact that tetracycline has a particle size D90 that has a value that is 4 micrometers to 10 micrometers, and a particle size D50 that has a value that is from 1 micrometer to 5 micrometers.
    [0003]
    3. Topical suspension formulation according to claim 1, characterized by the fact that tetracycline has a particle size D90 that has a value that is 4 micrometers to 10 micrometers, a particle size D50 that has a value that is 1 micrometer to 5 micrometers, and a D10 particle size that has a value that is 0.5 micrometers to 1.5 micrometers.
    [0004]
    Topical suspension formulation according to claim 1, characterized in that the tetracycline is minocycline or doxycycline, or a pharmaceutically acceptable salt, hydrates or polymorphs thereof.
    [0005]
    5. Topical suspension formulation according to claim 4, characterized by the fact that the minocycline concentration is from 0.05% to 10%.
    [0006]
    6. Topical suspension formulation, according to claim 5, characterized by the fact that the concentration of minocycline 4-epi is not more than 4% after storage for 6 months in real time (25 ° C / 60% relative humidity (RH) and under conditions of accelerated stability (40 ° C / 75% RH), as determined by HPLC analysis.
    [0007]
    7. Topical suspension formulation according to claim 5, characterized in that the concentration of minocycline 4-epi in the minocycline suspension formulation when stored at 40 ° C / 75% RH for one month results in less than 3% minocycline 4-epi, as determined by HPLC analysis;
    [0008]
    8. Topical suspension formulation according to claim 5, characterized in that the concentration of minocycline 4-epi in the minocycline suspension formulation when stored at 40 ° C / 75% RH for three months results in less than 4% minocycline 4-epi as determined by HPLC analysis.
    [0009]
    9. Topical suspension formulation according to claim 5, characterized by the fact that the concentration of minocycline 4-epi is not greater than 4% after storage for 12 months in real time (25 ° C / 60% RH) under conditions stability, as determined by HPLC analysis.
    [0010]
    10. Topical suspension formulation according to claim 1, characterized by the fact that the liquid medium is a non-comedogenic liquid medium.
    [0011]
    11. Topical suspension formulation according to claim 10, characterized in that the liquid non-comedogenic medium is one or more of a mineral oil, a light mineral oil, a minimal comedogenic oil and an additional non-comedogenic oil.
    [0012]
    12. Topical suspension formulation, according to claim 1, characterized by the fact that (ii) the non-comedogenic liquid medium being mineral oil.
    [0013]
    13. Topical suspension formulation according to claim 10, characterized in that the non-comedogenic liquid medium is defined as (a) resulting in less than 5% of the active ingredient tetracycline being dissolved in a medium at room temperature after 2 hours , as measured by HPLC and / or (b) resulting in less than 4% minocycline 4-epi, if minocycline is used as the active ingredient, when stored for 1 month at room temperature, as measured by HPLC.
    [0014]
    14. Topical suspension formulation according to claim 1, characterized by the fact that mineral oil constitutes at least 70% of the suspension formulation.
    [0015]
    15. Topical suspension formulation according to claim 1, characterized in that the polymeric hydrocarbon gelatinizing agent is a mixture of a mineral oil and one or more copolymers based on one or more monomers selected from alkene monomers, C1 -C10 or C1 to C6, or C2 to C4, and phenylalkene monomers, C1-C10, or C1 to C6, or C2 to C4, or is a gel comprising an oil and one or more gelatinizing polymers.
    [0016]
    16. Topical suspension formulation according to claim 15, characterized in that one or more copolymers comprise an ethylene / propylene / styrene copolymer.
    [0017]
    17. Topical suspension formulation according to claim 15, characterized in that one or more copolymers comprise a butylene / ethylene / styrene copolymer.
    [0018]
    18. Topical suspension formulation according to claim 15, characterized in that the suspension additionally comprises an antioxidant.
    [0019]
    19. Topical suspension formulation according to claim 15, characterized in that the polymeric gelatinizing agent comprises ethylene / propylene / styrene copolymer and butylene / ethylene / styrene copolymer and butylatedhydroxy toluene as an optional antioxidant.
    [0020]
    20. Topical suspension formulation according to claim 1, characterized in that the formulation is free of a skin penetration enhancing agent or an excipient that functions primarily or only as a skin penetration enhancer.
    [0021]
    21. Topical suspension formulation according to claim 1, characterized in that the formulation is free of a compound that results in dissolution of the active ingredient of tetracycline.
    [0022]
    22. Topical suspension formulation according to claim 21, characterized in that the compound that results in the dissolution of the tetracycline active ingredient comprises one or more of water, hydrophilic solvents and emollient esters;
    [0023]
    23. Topical suspension formulation according to claim 1, characterized in that the liquid medium comprises a mixture of a non-comedogenic medium and a comedogenic medium and the non-comedogenic medium is present in an amount greater than that of the comedogenic medium .
    [0024]
    24. Topical suspension formulation according to claim 1, characterized in that the composition consists essentially of the pharmaceutically effective amount of minocycline, a non-comedogenic liquid medium that does not dissolve or minimally dissolve tetracycline, and the polymeric hydrocarbon gelatinizing agent for thicken the composition and, optionally, one or more 4-epi minocycline, dyes, colorants, fragrances and a sun protection material.
    [0025]
    25. Topical suspension formulation according to claim 1, characterized in that the composition consists of a pharmaceutically effective amount of minocycline, a non-comedogenic liquid medium that does not dissolve or minimally dissolve tetracycline, and the polymeric hydrocarbon gelatinizing agent for thicken the composition.
    [0026]
    26. Topical suspension formulation according to claim 1, characterized in that the composition consists of a pharmaceutically effective amount of minocycline, a non-comedogenic liquid medium that does not dissolve or minimally dissolve tetracycline, and a gelatinizing agent to thicken the composition and 4-epi minocycline and, optionally, one or more of a comedogenic liquid medium present in a smaller amount than the non-comedogenic liquid medium, dyes, colorants, fragrances and sun protection materials.
    [0027]
    27. Topical suspension formulation according to claim 1, characterized in that the composition is non-foamable and free of a foam adjuvant.
    [0028]
    28. Topical suspension formulation according to claim 4, characterized in that minocycline is a free base of crystalline minocycline.
    [0029]
    29. Topical suspension formulation according to claim 1, characterized by the fact that it also comprises one or more of a sun protection agent, a fragrance and a colorant or dye.
    [0030]
    30. Topical suspension formulation according to claim 1, characterized in that it also comprises a pharmaceutically effective amount of a retinoid selected from tretionin, adapalene and tazarotene.
    [0031]
    31. Topical minocycline suspension formulation for use in the treatment of acne vulgaris, characterized by the fact that the composition essentially consists of a pharmaceutically effective amount of minocycline, a hydrophobic liquid medium that does not dissolve or minimally dissolve tetracycline, and a gelatinization agent of polymeric hydrocarbon to thicken the composition, where: - the hydrophobic liquid medium is defined as (a) resulting from less than 5% of the active ingredient tetracycline being dissolved in the medium at room temperature after 2 hours as determined by HPLC, and / or (b) resulting from less than 4% of 4-epi minocycline (when minocycline is used as an active ingredient) when stored for 1 month at room temperature, as determined by HPLC.
    [0032]
    32. Topical suspension formulation according to claim 1, characterized by the fact that tetracycline has a D90 particle size that has a value that is one of 4 micrometers, 5 micrometers, 6 micrometers, 7 micrometers, 8 micrometers or 9 micrometers , or a fractional value between any of those values.
    类似技术:
    公开号 | 公开日 | 专利标题
    US10213443B2|2019-02-26|Tetracycline topical formulations, preparation and uses thereof in treating an ocular condition
    KR101593579B1|2016-02-15|Therapeutic compositions
    US6299902B1|2001-10-09|Enhanced transdermal anesthesia of local anesthetic agents
    TW201114766A|2011-05-01|Pharmaceutical composition for a hepatitis C viral protease inhibitor
    US20130116271A1|2013-05-09|Tacrolimus-containing oil-in-water type creamy composition
    WO2017096530A1|2017-06-15|Decoquinate solid dispersion, method for preparing same and use thereof
    CN108057018A|2018-05-22|Colchicin topical composition and preparation method thereof
    BRPI1103229B1|2020-10-06|MICROPARTICULATE PHARMACEUTICAL COMPOSITIONS CONTAINING ANTIPARASITARIES FOR PROLONGED SUBCUTANEOUS THERAPY, USE OF THESE PHARMACEUTICAL COMPOSITIONS FOR THE PRODUCTION OF A MEDICINE AND METHOD OF TREATING PARASITES
    CN104771362B|2018-01-02|A kind of CLA ion pair lipide microsphere injection and preparation method thereof
    TW201215412A|2012-04-16|Stable pharmaceutical composition
    AU2021104317A4|2021-09-09|An Artemether-Loaded Nanostructured Lipid Carrier | Nanogel Composition and A Method for Formulation of the Artemether-Loaded | Nanogel
    WO2020021670A1|2020-01-30|Liquid topical preparation
    WO2005032516A1|2005-04-14|Formulation and manufacturing process of self-microemulsified aceclofenac soft capsules
    KR100196431B1|1999-06-15|Soft capsules formulations of biphenyl dimethyl dicarboxylate
    ES2387440B2|2014-02-04|TOPIC FORMULATIONS OF ANPHOTERICINE B AND METHOD OF OBTAINING
    CN106937944A|2017-07-11|A kind of injection metronidazole freeze-dried powder and preparation method thereof
    AU2020355603A1|2022-03-17|Rifaximin liquid formulations
    WO2021058656A1|2021-04-01|Rifaximin liquid formulations
    WO2014007239A1|2014-01-09|Composition containing amphotericin b
    同族专利:
    公开号 | 公开日
    EP2925293B1|2017-08-02|
    AU2013350941A1|2015-07-16|
    US10213443B2|2019-02-26|
    AU2013350941B2|2018-04-26|
    ES2645449T3|2017-12-05|
    RU2639591C2|2017-12-21|
    HUE034932T2|2018-03-28|
    IL239022A|2020-11-30|
    NO2925293T3|2017-12-30|
    PT106679B|2015-03-25|
    PL2925293T3|2017-12-29|
    RU2015122786A|2017-01-10|
    WO2014083311A1|2014-06-05|
    NZ708824A|2019-01-25|
    PT106679A|2014-05-27|
    DK2925293T3|2017-11-06|
    EP2925293A1|2015-10-07|
    ZA201504369B|2017-01-25|
    JP2016500095A|2016-01-07|
    US20170182071A1|2017-06-29|
    CA2895395A1|2014-06-05|
    MX2015006632A|2016-02-17|
    CN104902875A|2015-09-09|
    CA2895395C|2021-04-06|
    MX355174B|2018-04-09|
    US20140147504A1|2014-05-29|
    CN104902875B|2018-04-03|
    JP6444308B2|2018-12-26|
    KR20150104102A|2015-09-14|
    US9592246B2|2017-03-14|
    SG11201504145PA|2015-07-30|
    IL239022D0|2015-07-30|
    KR102235922B1|2021-04-05|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    GB769274A|1954-04-22|1957-03-06|Pfizer|Therapeutic preparations of tetracycline antibiotics in oil|
    GB1581335A|1976-07-05|1980-12-10|Leo Pharm Prod Ltd|16-s-acyl derivatives of fusidic acid|
    US4505896A|1979-04-19|1985-03-19|Elorac, Ltd.|Method of treating acne vulgaris and composition|
    JPS6353967B2|1980-10-06|1988-10-26|Miles Lab|
    US5122519A|1989-06-27|1992-06-16|American Cyanamid Company|Stable, cosmetically acceptable topical gel formulation and method of treatment for acne|
    US5874479A|1991-03-01|1999-02-23|Warner-Lambert Company|Therapeutic permeation enhanced-wound healing compositions and methods for preparing and using same|
    US6113921A|1993-03-23|2000-09-05|Pharmos Corp.|Topical and transdermal delivery system utilizing submicron oil spheres|
    US5905092A|1994-09-27|1999-05-18|Virotex Corporation Reel/Frame|Topical antibiotic composition providing optimal moisture environment for rapid wound healing that reduces skin contraction|
    US5747058A|1995-06-07|1998-05-05|Southern Biosystems, Inc.|High viscosity liquid controlled delivery system|
    SK284146B6|1996-02-16|2004-10-05|Janssen Pharmaceutica N. V.|Compositions containing an antifungal and a sulfur compound|
    JPH09255578A|1996-03-22|1997-09-30|Sekisui Chem Co Ltd|Preparation for external use for treating infectious skin disease|
    US5834008A|1996-09-19|1998-11-10|U.S. Biomaterials Corp.|Composition and method for acceleration of wound and burn healing|
    US6433068B1|1997-03-07|2002-08-13|David S. Morrison|Hydrocarbon gels as suspending and dispersing agents and products|
    AU763164B2|1998-05-08|2003-07-17|University Of Miami|Use of tetracyclines for treating meibomian gland disease|
    US20030007939A1|1998-07-31|2003-01-09|Howard Murad|Pharmaceutical compositions and methods for managing dermatological conditions|
    US6432934B1|1998-08-06|2002-08-13|Advanced Vision Research|Methods and compositions for topical treatment of eye surface inflammation and related dry eye disease|
    CN1320046A|1999-07-12|2001-10-31|三得利株式会社|Drug composition for topical administration|
    US6946118B1|1999-09-14|2005-09-20|Orapharma, Inc.|Formulations for treating or preventing mucositis|
    US6667045B2|1999-10-01|2003-12-23|Joseph Scott Dahle|Topical applications for skin treatment|
    US20030077301A1|1999-12-16|2003-04-24|Maibach Howard I.|Topical pharmaceutical composition for the treatment of inflammatory dermatoses|
    US6967023B1|2000-01-10|2005-11-22|Foamix, Ltd.|Pharmaceutical and cosmetic carrier or composition for topical application|
    US8512718B2|2000-07-03|2013-08-20|Foamix Ltd.|Pharmaceutical composition for topical application|
    US20020010162A1|2000-03-02|2002-01-24|Raul Fleischmajer|Treatment of psoriasis with matrix metalloproteinase inhibitors|
    US7758888B2|2000-04-21|2010-07-20|Sol-Gel Technologies Ltd.|Composition exhibiting enhanced formulation stability and delivery of topical active ingredients|
    JP4653282B2|2000-05-23|2011-03-16|昭和薬品化工株式会社|Minocycline-containing composition|
    US20040115261A1|2001-04-05|2004-06-17|Ashley Robert A.|Controlled delivery of tetracycline compounds and tetracycline derivatives|
    AU2002317053B2|2001-07-27|2004-08-05|Vital Health Sciences Pty Ltd|Dermal therapy using phosphate derivatives of electron transfer agents|
    AU2003242647B2|2002-06-17|2009-10-22|Naicons S.C.A.R.L.|Use of amide derivative of GE 2270 factor A3 for the treatment of acne|
    US20040076699A1|2002-07-15|2004-04-22|Chaudhuri Ratan K.|Topical anhydrous delivery system|
    US7700076B2|2002-10-25|2010-04-20|Foamix, Ltd.|Penetrating pharmaceutical foam|
    US7575739B2|2003-04-28|2009-08-18|Foamix Ltd.|Foamable iodine composition|
    KR100738264B1|2003-06-11|2007-07-12|더 프록터 앤드 갬블 캄파니|Preparation-at-use device comprising pre-formed hydrogel product|
    US8486374B2|2003-08-04|2013-07-16|Foamix Ltd.|Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses|
    US7820145B2|2003-08-04|2010-10-26|Foamix Ltd.|Oleaginous pharmaceutical and cosmetic foam|
    US7704518B2|2003-08-04|2010-04-27|Foamix, Ltd.|Foamable vehicle and pharmaceutical compositions thereof|
    US7241746B2|2003-08-06|2007-07-10|Regena Therapeutics, Lc|Method and composition for treating periodontal disease|
    SI1791791T1|2004-09-27|2019-10-30|Special Water Patents B V|Methods and compositions for treatment of water|
    US7531164B2|2005-10-21|2009-05-12|Duke University|Preventing bacterial or viral infectivity and composition containing infection preventing additive|
    GB2432529B|2005-11-25|2008-04-23|Univ Feng Chia|Antimicrobial compositions and wound dressings|
    JP4959991B2|2006-03-03|2012-06-27|株式会社日本点眼薬研究所|Suspension pharmaceutical composition containing tranilast or a pharmacologically acceptable salt thereof|
    US20080188446A1|2007-02-02|2008-08-07|Warner Chilcott Company Inc.|Tetracycline compositions for topical administration|
    WO2008097850A1|2007-02-02|2008-08-14|Warner Chilcott Company, Inc.|Tretracycline compositions for topical administration|
    JP2010520210A|2007-02-28|2010-06-10|アーシエックスセラピューティックス，インコーポレイテッド|Methods and compositions for normalizing meibomian gland secretions|
    WO2008118744A1|2007-03-23|2008-10-02|Molecular Research Center, Inc.|Anti-inflammatory compositions comprising tetracyclines and use thereof in therapy|
    DK2079441T3|2007-07-25|2010-12-13|Ixodes Gmbh|Topical antibiotic composition to prevent Lyme's disease|
    WO2009090495A2|2007-12-07|2009-07-23|Foamix Ltd.|Oil and liquid silicone foamable carriers and formulations|
    US8518376B2|2007-12-07|2013-08-27|Foamix Ltd.|Oil-based foamable carriers and formulations|
    GB0800145D0|2008-01-04|2008-02-13|Reckitt Benckiser Uk Ltd|Skincare treatment|
    US20110092438A1|2008-03-28|2011-04-21|Angesmg, Inc.|Composition for external application comprising transcription factor decoy as active ingredient|
    EP2282714B1|2008-04-29|2017-12-13|Hair Systems, Inc.|Composition and method for cream bleach product|
    US20100029765A1|2008-07-30|2010-02-04|Ranbaxy Labortories Limited|Topical aqueous composition comprising tretinoin|
    AU2009282659A1|2008-08-18|2010-02-25|Nanotherapeutics, Inc.|Topical hydrogel composition|
    US20120087872A1|2009-04-28|2012-04-12|Foamix Ltd.|Foamable Vehicles and Pharmaceutical Compositions Comprising Aprotic Polar Solvents and Uses Thereof|
    PT104644B|2009-06-26|2012-11-06|Hovione Farmaciencia S A|Topical formulation containing a tetracycline and a method of treating skin infections using the same|
    US9155915B2|2009-07-27|2015-10-13|Dermadoctor, Inc.|Moisturizing retinol composition|
    WO2011138678A2|2010-05-04|2011-11-10|Foamix Ltd.|Compositions, gels and foams with rheology modulators and uses thereof|
    GB2474930B|2009-10-02|2012-07-04|Foamix Ltd|Topical tetracycline compositions|
    CA2776366C|2009-10-02|2017-07-18|Foamix Ltd.|Surfactant-free water-free foamable compositions, breakable foams and gels and their uses|
    US9328162B2|2010-02-25|2016-05-03|Schepens Eye Research Institute|Therapeutic compositions for the treatment of dry eye disease|
    US20120076766A1|2010-04-21|2012-03-29|Phillips D Howard|Topical drug delivery system with dual carriers|
    PT105116B|2010-05-14|2012-10-16|Hovione Farmaciencia S A|NEW PARTICLES OF TETRACYCLINE AND PROTEIN AGENT.|
    BRPI1002601E2|2010-06-01|2020-06-30|Embrapa Pesquisa Agropecuaria|nanostructured composition for veterinary use for drug administration|
    US20120093876A1|2010-10-13|2012-04-19|Aciex, Inc.|Ophthalmic Formulations, Methods Of Manufacture And Methods of Normalizing Meibomian Gland Secretions|
    CA2719512A1|2010-11-01|2012-05-01|Stiefel Research Australia Pty Ltd|Polymeric topical compositions|
    WO2012103037A1|2011-01-24|2012-08-02|Anterios, Inc.|Oil compositions|US7700076B2|2002-10-25|2010-04-20|Foamix, Ltd.|Penetrating pharmaceutical foam|
    US9211259B2|2002-11-29|2015-12-15|Foamix Pharmaceuticals Ltd.|Antibiotic kit and composition and uses thereof|
    US10117812B2|2002-10-25|2018-11-06|Foamix Pharmaceuticals Ltd.|Foamable composition combining a polar solvent and a hydrophobic carrier|
    US9265725B2|2002-10-25|2016-02-23|Foamix Pharmaceuticals Ltd.|Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof|
    NZ540166A|2002-10-25|2007-06-29|Foamix Ltd|Cosmetic and pharmaceutical foam|
    IL152486D0|2002-10-25|2003-05-29|Meir Eini|Alcohol-free cosmetic and pharmaceutical foam carrier|
    US20080138296A1|2002-10-25|2008-06-12|Foamix Ltd.|Foam prepared fromnanoemulsions and uses|
    US9668972B2|2002-10-25|2017-06-06|Foamix Pharmaceuticals Ltd.|Nonsteroidal immunomodulating kit and composition and uses thereof|
    US7704518B2|2003-08-04|2010-04-27|Foamix, Ltd.|Foamable vehicle and pharmaceutical compositions thereof|
    US20080260655A1|2006-11-14|2008-10-23|Dov Tamarkin|Substantially non-aqueous foamable petrolatum basedpharmaceutical and cosmetic compositions and their uses|
    US8636982B2|2007-08-07|2014-01-28|Foamix Ltd.|Wax foamable vehicle and pharmaceutical compositions thereof|
    US9439857B2|2007-11-30|2016-09-13|Foamix Pharmaceuticals Ltd.|Foam containing benzoyl peroxide|
    WO2009090495A2|2007-12-07|2009-07-23|Foamix Ltd.|Oil and liquid silicone foamable carriers and formulations|
    US20120087872A1|2009-04-28|2012-04-12|Foamix Ltd.|Foamable Vehicles and Pharmaceutical Compositions Comprising Aprotic Polar Solvents and Uses Thereof|
    CA2769677A1|2009-07-29|2011-02-03|Foamix Ltd.|Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses|
    CA2769625C|2009-07-29|2017-04-11|Foamix Ltd.|Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses|
    US9849142B2|2009-10-02|2017-12-26|Foamix Pharmaceuticals Ltd.|Methods for accelerated return of skin integrity and for the treatment of impetigo|
    CA2776366C|2009-10-02|2017-07-18|Foamix Ltd.|Surfactant-free water-free foamable compositions, breakable foams and gels and their uses|
    EP3229908A4|2014-12-12|2018-06-27|Schepens Eye Research Institute. Inc.|Gdnf induction for the treatment of retinal disorders|
    JP2018506554A|2015-02-25|2018-03-08|サン、ファーマ、アドバンスト、リサーチ、カンパニー、リミテッドＳｕｎ Ｐｈａｒｍａ Ａｄｖａｎｃｅｄ Ｒｅｓｅａｒｃｈ Ｃｏｍｐａｎｙ Ｌｉｍｉｔｅｄ|Nanoparticle composition|
    CA2980527A1|2015-03-23|2016-09-29|BioPharmX, Inc.|Pharmaceutical tetracycline composition for dermatological use|
    CN105380900B|2015-11-25|2018-05-29|徐州医学院|A kind of nano magnetic therapy external-use gel for treating acne and its preparation method and application|
    US10398641B2|2016-09-08|2019-09-03|Foamix Pharmaceuticals Ltd.|Compositions and methods for treating rosacea and acne|
    CA3078783A1|2017-10-24|2019-05-02|Glenmark Pharmaceuticals Limited|Topical pharmaceutical composition of adapalene and minocycline|
    RU2020125984A3|2018-01-07|2022-02-07|
    US11202788B2|2019-08-22|2021-12-21|Nanopharmaceutics, Inc.|Topical doxycycline hydrogel with improved long-term stability|
    US20210308154A1|2020-03-24|2021-10-07|Hovione Scientia Limited|Methods and Compositions for Treating Meibomian Gland Dysfunction|
    US20220062308A1|2020-08-27|2022-03-03|Hovione Scientia Limited|Methods and compositions for treating rosacea|
    法律状态:
    2018-01-23| B07D| Technical examination (opinion) related to article 229 of industrial property law|
    2018-03-06| B06F| Objections, documents and/or translations needed after an examination request according art. 34 industrial property law|
    2018-03-13| B06F| Objections, documents and/or translations needed after an examination request according art. 34 industrial property law|
    2018-03-20| B06I| Technical and formal requirements: publication cancelled|Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA. |
    2019-05-21| B07E| Notice of approval relating to section 229 industrial property law|Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
    2019-08-20| B06U| Preliminary requirement: requests with searches performed by other patent offices: suspension of the patent application procedure|
    2020-12-29| B09A| Decision: intention to grant|
    2021-02-23| B16A| Patent or certificate of addition of invention granted|Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 08/11/2013, OBSERVADAS AS CONDICOES LEGAIS. |
    优先权:
    申请号 | 申请日 | 专利标题
    PT106679|2012-11-27|
    PT106679A|PT106679B|2012-11-27|2012-11-27|TOPICAL FORMULATIONS OF TETRACYCLINES, THEIR PREPARATION AND USES|
    PCT/GB2013/052939|WO2014083311A1|2012-11-27|2013-11-08|Tetracycline topical formulations, preparation and uses thereof|
    [返回顶部]